Edgewise Therapeutics Inc EWTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
/C O R R E C T I O N - Edgewise Therapeutics/
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Trading Information
- Previous Close Price
- $47.57
- Day Range
- $45.04–46.93
- 52-Week Range
- $19.76–48.78
- Bid/Ask
- $40.98 / $47.00
- Shares Outstanding
- 109.48M
- Market Cap
- $5.02B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 2.70
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 133
- Website
- https://www.edgewisetx.com
Valuation
Metric | EWTX |
|---|---|
Price/Earnings (Normalized) | 2.70 |
Price/Book Value | 3.07 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | EWTX |
|---|---|
Quick Ratio | 12.10 |
Current Ratio | 12.30 |
Interest Coverage | — |
Quick Ratio
EWTX
Profitability
Metric | EWTX |
|---|---|
Return on Assets (Normalized) | 4.27% |
Return on Equity (Normalized) | 4.57% |
Return on Invested Capital (Normalized) | 1.31% |
Return on Assets
EWTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|n@DP?nM | LOCK|$Y!>! | $138B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|?h@<M$ | LOCK|<%@^$ | $98B | |||
| Moderna Inc MRNA | LOCK|yMfV?^ | LOCK|nP | $94B | |||
| argenx SE ADR ARGX | LOCK|g#?lCt | LOCK|Nw | $62B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|Qrbqn$& | LOCK|QV | $50B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|#<%>#DGn | LOCK|TnfS | $31B | |||
| Incyte Corp INCY | LOCK|y<<Wq#! | LOCK|nSL | $25B | |||
| BioNTech SE ADR BNTX | LOCK|?sDz>zb | LOCK|l! | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|JQ!#P#? | LOCK|&w?wP | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|X%%Qs?! | LOCK|xN! | $15B |
United States